Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement

Biochemistry, Genetics and Molecular Biology

• Mutation 100%
• Epidermal Growth Factor Receptor 80%
• Wild Type 70%
• Anaplastic Lymphoma Kinase 60%
• KRAS 60%
• Genotyping 50%
• Smoking 40%
• Nested Gene 20%
• Receptor Tyrosine Kinase Inhibitors 20%
• Survival 20%
• Kinase 10%
• Gene Mutation 10%
• Overall Survival 10%
• Fluorescence in Situ Hybridization 10%
• Exon 10%
• Virus Oncogene 10%
• Codon 10%
• Gene Rearrangement 10%
• Progression Free Survival 10%
• Ras2 10%
• Sample 10%
• Sequencing 10%
• Rat 10%
• Genetics 10%